Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could giving TB meds at home boost prevention?

NCT ID NCT06214910

Prevention Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tested whether giving a full 3-month supply of TB preventive medicine directly in the community helps more people finish their treatment compared to standard clinic visits. Researchers enrolled 301 adults in South Africa who were at risk for TB, including those with HIV or close contact with TB patients. The goal was to see if community delivery leads to higher completion rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
isoniazid plus rifapentine (3HP)
What this could lead to
If successful, this approach could make it easier for people to complete TB preventive therapy, reducing tuberculosis cases in high-risk communities.
What could go wrong
This is a small, completed study focused on feasibility and completion rates, not on long-term TB prevention. Results may not apply to other settings or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

301 people

The number who actually took part.

Started

Feb 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age * Living in the study catchment area * Eligible for TPT according to South African National guidelines(5), i.e. are a) living with HIV or b) are a close contact of a person with TB disease (defined by a person that resides in the same house as a person with TB), c) and in either case * Have screened negative for TB disease in the last 6 months, through TB TRIAGE+ Trial, other household contact tracing, or other community TB screening * Negative TB screening at enrolment (if TB TRIAGE+ screening was more than 3 months ago) * Willing and able to provide written or verbal consent * Participants whom have not received TPT in the last 12 months; this was confirmed verbally with participants during the enrolment process. Exclusion Criteria: * Less than 18 years of age. * Pregnant or planning on pregnancy within next three months * Planning on moving or relocating from the area within the next three months * Positive for active TB * Currently on TB treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV I infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV I infection Tuberculosis

Contacts and locations

Locations

  • Human Sciences Research Council

    Sweetwaters, KwaZulu-Natal, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.